Company intelligence / Profile preview

Kapha Bio

Boston / Bay Area, Massachusetts / California, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Kapha Bio is developing a new category of patented biomaterials designed to enhance the body’s natural defenses against recurrent infections caused by pathogenic bacteria. The company aims to address the root causes of these infections and reduce their recurrence, but no clinical results have been published yet[2][1][3].

Therapeutic areas: Infectious Diseases
Modalities: Biomaterials (patented biomaterials for infection defense)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Kapha Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kapha Bio.

Explore the full profile